JP2022001604A - Hyperglycemic inhibitor and intestinal function-controlling medicine - Google Patents

Abstract

To provide a hyperglycemic inhibitor which is significantly improved in blood glucose level rise inhibitory action and an intestinal function-controlling medicine which is significantly improved in controlling action for intestinal functions.SOLUTION: Provided are a hyperglycemic inhibitor and an intestinal function-controlling medicine which contain a processed product of barley and a processed product of at least one plant material selected from a group consisting of hop, mulberry, chlorella, kale, Peucedanum japonicum Thunb., sweet potato, Terminalia plants, turmeric, ginger, soybean, Salacia, gymnema, guava, and Eucommia ulmoides.SELECTED DRAWING: Figure 1

Description

The present invention relates to a blood glucose level increase inhibitor and an intestinal regulator, and more particularly to a blood glucose level increase inhibitor and an intestinal regulator containing a barley-treated product and a specific plant material-treated product as active ingredients.

For example, a collagen absorption promoter containing young barley leaves (see Patent Document 1) and SOD (superoxide dismutase) containing young barley leaves as an active ingredient promote gene expression in pursuit of the function of the processed barley product. There is an agent (see Patent Document 2).

Japanese Unexamined Patent Publication No. 2013-255512 Japanese Unexamined Patent Publication No. 2015-14038

An object of the present invention is to provide a blood glucose level increase inhibitor having a dramatically improved blood glucose level increase inhibitory effect and an intestinal regulating agent having a dramatically improved intestinal regulation effect, which contains a processed barley product.

Dietary fiber is believed to be effective in suppressing the rapid rise in blood glucose levels that rise after a meal. The present inventors focused on a plant material rich in dietary fiber, first selected barley young leaves, rice young leaves, wheat young leaves, and cabbage as the main materials of the plant material, and blood glucose regarding the action and effect of the combination with hop leaves. As a result of investigating the effect of suppressing the increase in value, the best effect was shown when young barley leaves were used.

Therefore, the present inventors diligently investigated and studied the blood glucose increase inhibitory effect on the combination of the young barley leaves and other plant materials, and found that the blood glucose increase inhibitory effect by combining the barley processed product with a specific plant material. I found that it can be dramatically improved. That is, there is almost no effect of suppressing the increase in blood glucose level, or even if there is such an effect, by combining the plant material with the processed barley product, the effect of suppressing the increase in blood glucose level can be achieved as compared with the case of the treated barley product alone. I found that it could be dramatically improved. At the same time, by combining a plant material having little or little intestinal regulating effect with the barley-treated product, the intestinal-regulating effect can be dramatically improved as compared with the case of the barley-treated product alone. I found what I could do.

That is, the present invention is at least one selected from the group consisting of processed barley, terminaria, hops, quail, chlorella, kale, long-lived grass, sweet potato, curcuma longa, ginger, soybean, salasia, gymnema, guaba, and eucommia. The present invention relates to a processed product of a plant material and an agent for suppressing an increase in blood glucose level, which is characterized by containing.

In addition, the present invention is at least one selected from the group consisting of barley processed products, terminaria, hops, mulberry, chlorella, kale, long-lived grass, sweet potato, curcuma longa, ginger, soybean, salasia, gymnema, guaba, and tochu. The present invention relates to a processed product of a plant material and an intestinal regulator characterized by containing.

In addition, the present invention contains a processed barley product as an active ingredient, and is further selected from the group consisting of terminaria, hops, quail, chlorella, kale, long-lived grass, sweet potato, curcuma longa, ginger, soybean, salasia, gymnema, guaba, and tochu. The present invention relates to an agent for suppressing an increase in blood glucose level, which comprises a processed product of at least one kind of plant material as an active ingredient.

In addition, the present invention contains a processed barley product as an active ingredient, and is selected from the group consisting of terminaria, hops, quail, chlorella, kale, long-lived grass, sweet potato, curcuma longa, ginger, soybean, salasia, gymnema, guaba, and tochu. The present invention relates to an intestinal regulator characterized by containing a processed product of one kind of plant material as an active ingredient.

The form of the blood glucose level increase inhibitor and the intestinal regulator is preferably tablets, granules, powders or capsules.

According to the blood glucose level increase inhibitor of the present invention, the blood glucose level increase inhibitory effect can be dramatically improved as compared with the case of the barley-treated product alone. Further, according to the intestinal regulating agent of the present invention, the intestinal regulating action can be dramatically improved as compared with the case of the barley-treated product alone.

It is a figure which shows the measurement result (change value) of the blood glucose level of the male KK-Ay mouse to which the blood glucose increase inhibitor of this invention was applied. It is a figure which shows the measurement result of the number of feces for 24 hours of a male KK-Ay mouse to which the intestinal regulating agent of this invention was applied. It is a figure which shows the measurement result (change value) of the body weight of the male KK-Ay mouse to which the agent of this invention was applied.

The blood glucose increase inhibitor and intestinal regulator of the present invention are composed of a group consisting of a barley-treated product, terminaria, hops, quail, chlorella, kale, long-lived grass, sweet potato, curcuma longa, ginger, soybean, salasia, gymnema, guava, and Tochu. It is characterized by containing a processed product of at least one selected plant material (hereinafter, may be referred to as a secondary material). As the auxiliary material, one type may be used alone, or two or more types may be mixed and used.

The barley processed product and the plant material processed product used for the blood glucose level increase inhibitor and the intestinal regulating agent of the present invention may be any part of the plant such as leaves, stems, roots, flowers, fruits, trunks and branches. Processed plant material such as crushed plant material, squeezed juice, and extract can be used. Examples of the crushed product include powder, granules and the like. The juice or extract may be liquid, but can also be used as a paste or a dry powder. The extract can be obtained by extracting with a suitable solvent, and may be heated if necessary. As the extraction solvent, for example, a water-soluble solvent such as water, ethanol, or hydrous ethanol can be used. As these barley processed products and auxiliary material processed products, commercially available products can be used.

[Processed barley]
As the barley, two-row barley, six-row barley and the like can be used. As the site used in the present invention, stems and leaves are preferable, and young leaves are particularly preferable.

[Secondary material]
(Terminaria)
Examples of the terminaria include Terminalia bellirica (belerica), Terminalia catappa, Terminalia tomentosa, Terminalia citrina, Terminalia phellocarpa, Terminalia copelandii, Terminalia brassi, Terminalia ivorensis, Terminalia superba, Terminalia arjuna, Terminalia chebula and the like. Of these, Terminalia bellirica (belerica) and Terminalia chebula are preferable. As the site used in the present invention, fruits excluding seeds are preferable, and the peel or flesh of fruits excluding seeds is most preferable.
(hop)
Hops are vine perennials of the family Cannabaceae. As the site used in the present invention, vines and leaves are preferable.

(Morus alba)
Morus alba is a plant belonging to the genus Morus alba in the family Morus alba. As the site used in the present invention, stems and leaves are preferable, and leaves are particularly preferable.
(chlorella)
Chlorella is a freshwater unicellular green alga of the genus Chlorella. As the chlorella used in the present invention, whole algae of chlorella obtained by culturing by a conventional method can be used, and this culture solution, a concentrate of whole chlorella algae, a dry powder, or the like can be used.

(Kale)
Kale is a Brassicaceae plant, and leaves and stems are preferable as the site used in the present invention. The kale variety is not particularly limited, and various types of kale such as kitchen kale, tree kale, bush kale, mallow kale, collard, and green leaf kale can be used.
(Longevity grass)
Long-lived grass is a perennial plant that belongs to the genus Peucedanum terrestris in the Umbelliferae family. Stems and leaves are preferable as the sites used in the present invention.

(Sweet potato)
Sweet potato is a plant belonging to the family Convolvulaceae, and is generally called sweet potato. The variety of sweet potato is not particularly limited, and examples thereof include sweet potato, Joy White, Koganesengan, Shiroyutaka, sweet potato starch, and Ayamurasaki. As the site used in the present invention, stems and leaves are preferable, and young leaves are particularly preferable.
(Curcuma longa)
Turmeric is a perennial plant belonging to the genus Curcuma longa in the family Zingiberaceae, and has been used as a dye and fragrance for a long time. Examples of the type of curcuma longa include spring curcuma longa (curcuma longa), autumn curcuma longa, purple curcuma longa (zedoary), and the like, and autumn curcuma longa is particularly preferable. Rhizome is preferable as the site used in the present invention.

(Ginger)
Ginger is a plant belonging to the genus Ginger of the family Zingiberaceae, and examples thereof include Sanshu ginger, Huang ginger, Kintoki ginger, and Tananaka ginger. Rhizome is preferable as the site used in the present invention.
(soy)
Soybean is an annual plant belonging to the genus Glycine of the family Leguminosae, and examples thereof include black beans, red beans, green soybeans, white soybeans, and Kurosaki tea beans. Seeds are preferred as the site used in the present invention. Further, the soybean may be a processed product, and soybean flour is particularly preferable.

(Salacia)
Salacia is a plant belonging to the genus Salacia of the family Salacia, which grows mainly in Sri Lanka, India and Southeast Asian regions. Is particularly preferable. Roots are preferred as the site used in the present invention.

(Gurmar)
Gymnema is a vine belonging to the Apocynaceae family that reduces production in India and Sri Lanka, and examples thereof include Gymnema sylvestre. Stems and leaves are preferable as the sites used in the present invention.
(Guava)
Guava is a plant of the genus Guava in the family Myrtaceae, for example, Psidium guajava L. et al. Can be mentioned. Stems and leaves are preferable as the sites used in the present invention.

(Tochu)
Eucommia ulmoides is a deciduous tree native to China, and as the site used in the present invention, stems and leaves are preferable, and Eucommia ulmoides leaves plucked before the leaves fall are particularly preferable.

[Other materials]
(Pullulan)
Pullulan is a water-soluble polysaccharide in which maltotriose consisting of three glucoses with α-1,4 bonds is bound in a chain by repeating α-1,6 bonds. When this pullulan is alone in a barley processed product, it has the same effect as the above-mentioned auxiliary material. Pullulan can be added to the barley processed product alone or in combination with the above-mentioned auxiliary materials. As the raw material of pullulan, fermented starch derived from corn, potatoes, sweet potatoes and the like can be used. Filamentous fungi can be used for fermentation, and examples of the filamentous fungi include Aureobasidium pullulans.

The compounding mass ratio of the barley-processed product and the plant-processed product is preferably in the range of 0.02: 1 to 100: 1, and preferably in the range of 0.05: 1 to 50: 1 in terms of dry mass. Is more preferable, and the range of 0.1: 1 to 40: 1 is more preferable, and the range of 0.5: 1 to 30: 1 is particularly preferable. When the blending ratio of the barley-processed product and the plant-processed product is within the above range, the effect of the present invention can be more effectively exhibited.

The content of the barley-treated product and the plant-treated product (active ingredient) in the blood glucose level increase inhibitor and the intestinal regulator of the present invention may be appropriately contained within the range in which the effect is exhibited. In the blood glucose level increase inhibitor, the active ingredient is preferably contained in an amount of 0.01 to 100% by mass, more preferably 0.1 to 85% by mass, and 0, in terms of dry mass. It is more preferably contained in an amount of 5 to 70% by mass.

The blood glucose level increase inhibitor and intestinal regulator of the present invention can be used as an oral preparation, and the intake thereof is not particularly limited, but from the viewpoint of exerting the effect of the present invention more remarkably, the active ingredient per day. It is preferable to take it so that the intake amount is 500 mg / day or more, more preferably 1000 mg / day or more, and further preferably 1500 mg / day or more. The blood glucose level increase inhibitor and the intestinal regulator of the present invention are contained in one container or, for example, divided into a plurality of containers of 2 to 3 so that the daily intake becomes the above-mentioned intake, and are contained as one day's worth. be able to.

Further, in particular, in the blood glucose level increase inhibitor of the present invention, from the viewpoint of exerting the effect of the present invention more remarkably, the daily intake as the amount of dietary fiber should be 600 mg / day or more. It is more preferable to take it so as to be 1200 g / day or more, and it is further more preferable to take it so as to be 1800 g / day or more. The blood glucose level increase inhibitor of the present invention may be contained in one container or divided into a plurality of containers, for example, 2 to 3 so that the daily intake becomes the above-mentioned intake. can.

Further, particularly in the intestinal regulating agent of the present invention, from the viewpoint of exerting the effect of the present invention more remarkably, it is preferable to ingest the dietary fiber so that the daily intake is 650 mg / day or more, 1300 g. It is more preferable to take it so as to be 1950 mg / day or more, and it is further preferable to take it so as to be 1950 mg / day or more. The intestinal regulating agent of the present invention can be contained in one container or divided into a plurality of containers, for example, 2 to 3 so that the daily intake becomes the above-mentioned intake, and can be contained as one day's worth.

The blood glucose level increase inhibitor and intestinal regulating agent of the present invention contain a barley processed product and a predetermined plant treated product, and can be distinguished from other products as a product in that they are used for blood glucose level increase suppressing or intestinal regulation. If this is the case, the present invention is not particularly limited, and for example, a drug indicating that the main body of the product, the packaging, the instruction manual, or the advertised material according to the present invention has a function of suppressing an increase in blood glucose level and / or regulating an intestine. Is included in the scope of the present invention.

The blood glucose level increase inhibitor and intestinal regulating agent of the present invention can be produced by a known pharmaceutical method by adding an excipient or the like acceptable for oral use, if necessary. Examples of the excipient include calcium stearate, silicon dioxide, sucrose fatty acid ester, glycerin fatty acid ester, maltose, reduced maltose, reduced palatinose, cellulose, and hydroxypropyl cellulose.

The forms of the blood glucose level increase inhibitor and the intestinal regulator of the present invention include, for example, tablets, granules, powders, capsules, liquids, granules, rods, plates, blocks, solids, and rounds. Examples thereof include agents, paste-like agents, cream-like agents, capsule-like agents, gel-like agents, chewable agents, stick-like agents and the like. Among these, the forms of tablets, granules, powders, capsules and liquids are particularly preferable.

In addition, the blood glucose level increase inhibitor and the intestinal regulating agent of the present invention may contain components other than the barley-treated product and the predetermined plant-treated product, if necessary. Ingredients other than barley processed products and predetermined plant processed products include, for example, water-soluble vitamins (vitamins B1, B2, B3, B5, B6, B12, B13, B15, B17, biotin, choline, folic acid, inositol, PABA, etc. Vitamins such as vitamin C, vitamin P) and oil-soluble vitamins (vitamins A, D, E, K); minerals such as calcium, magnesium, phosphorus, iron; sulfur-containing compounds contained in taurine, garlic, etc .; hesperidin, Flavonoids or flavonoids such as quercetin; proteins such as collagen; peptides; amino acids; animal fats and oils; vegetable fats and oils; crushed products or extracts of animals and plants can be mentioned.

Hereinafter, the present invention will be described based on examples.
[Example 1]
After a habituation period or a rest period in 8- to 19-week-old male KK-Ay mice (model mice that spontaneously develop type 2 diabetes and develop obesity and hyperglycemia), blood glucose and body weight levels become uniform. It was grouped as follows. Each test group was allowed to freely ingest the test feed shown in Table 1 for 4 days.

For barley, dried and crushed young leaves were used.
For hops, dried ground powder of leaves and vines was used.
For morus alba, dried crushed powder of stems and leaves was used.
For chlorella, commercially available chlorella micropowder was used.
For kale, dried and crushed leaves were used.
For longevity grass, dried crushed powder of stems and leaves was used.
For sweet potatoes, dried and crushed powder of young leaves was used.
For terminaria, dried ground powder of water extract of fruit and peel of terminaria beryrica was used.
For curcuma longa, dried and crushed powder of the rhizome of autumn curcuma longa was used.
For ginger, dried and crushed rhizome powder was used.
For soybeans, commercially available soybean flour was used.
For Salacia, a dry powder of hydrous ethanol extract of Salacia reticular root was used.
For Gymnema, a dry powder of hydrous ethanol extract from the leaves of Gymnema sylvestre was used.
For guava, a guava polyphenol concentrate (powder) extracted from the leaves with hydrous ethanol was used.
For Tochu, dry powder of hot water extract of leaves was used.

A blood glucose level measurement test, an intestinal regulation effect confirmation test, and a body weight measurement test were performed for each test group. Specifically, it is as follows.

(Blood glucose measurement test)
At the time of grouping (day 0 of the test) and on the third day of the test, after fasting for about 1 hour, blood was collected from the tail vein and the blood glucose level (mg / dL) was measured. A small blood glucose meter (Glutest Ace; Sanwa Kagaku Kenkyusho Co., Ltd.) was used for the measurement.

FIG. 1 shows the measurement result (change value) of the blood glucose level. In the embodiment of the present invention in which barley and the auxiliary materials are mixed with respect to the blood glucose level of the standard feed alone or the feed in which the standard feed is mixed with barley or each auxiliary material alone, the blood glucose level is in each case. A decrease was observed, and the synergistic effect of barley and each auxiliary material was confirmed.

(Intestinal regulation effect confirmation test)
On the 4th day of the test, 24 hours of stool was collected before the measurement, and the number of stools for 24 hours was counted.

FIG. 2 shows the measurement result of the number of feces. Compared to the control of only the standard feed and the number of feces of the feed in which barley or each auxiliary material is mixed alone in the standard feed, the number of feces is clarified in the embodiment of the present invention in which barley and the auxiliary material are mixed. It increased, and the synergistic intestinal regulation effect of barley and each auxiliary material was confirmed.

(Weight measurement test)
Body weight was measured with an electronic balance at the time of grouping (test day 0) and on the test day 4.

FIG. 3 shows the measurement result (change value) of the body weight. In any case in the embodiment of the present invention in which barley and auxiliary materials are blended, compared to the control of only the standard feed and the rate of weight gain of the feed in which barley and each auxiliary material are blended alone in the standard feed. The rate of weight gain was small, and the synergistic effect of barley and each auxiliary material was confirmed.

[Reference example]
The test was carried out in the same manner as in Example 1 using pullulan instead of the above sub-material. As a result, in the blood glucose level measurement, the amount of change was about +210 mg / dL in the feed containing pullulan alone, but it was significantly reduced to about -145 mg / dL in the barley and pullulan mixed feeds. And the synergistic effect of pullulan was confirmed. In addition, in the confirmation of the intestinal regulation effect, the number of feeds containing pullulan alone was 61, but the number of feeds containing barley and pullulan was 95, confirming the synergistic effect of barley and pullulan. Furthermore, in the weight measurement, the amount of change was about +1.3 g in the feed containing pullulan alone, but it was about +0.2 g in the feed containing barley and pullulan, confirming the synergistic effect of barley and pullulan. ..

[Example 2] (Manufacturing of tablets)
Each component was mixed at the ratio shown below, and the lock was applied by a lock press.

Ingredient composition (mg)
Barley young leaf powder 135
Hop leaf end 15
Dextrin 120
Vitamin preparation 15
Anhydrous citric acid 15

By ingesting about 4 to 10 tablets per day (intake of the active ingredient 600 to 1500 mg per day), it is expected that an effect of suppressing an increase in blood glucose level and / or an effect of intestinal regulation can be obtained.

[Example 3] (Production of capsule)
15 parts by weight of young barley leaf powder was mixed with 1 part by weight of chlorella powder to prepare granules according to a conventional method, and 300 mg of the granules were filled in capsules to prepare capsules.

By ingesting 6 capsules per day (intake of the active ingredient 1800 mg per day), it is expected that an effect of suppressing an increase in blood glucose level and / or an effect of intestinal regulation can be obtained.

[Example 4] (Production of granules)
15 parts by weight of the processed barley product was mixed with 1 part by weight of ginger powder to prepare granules according to a conventional method, and 1.8 g of the granules was packaged in an aluminum stick.

It is expected that the effect of suppressing the increase in blood glucose level and / or the effect of intestinal regulation can be obtained by ingesting 3 bags of this granule per day (intake of the active ingredient per day is 5400 mg).

The blood glucose level increase inhibitor and intestinal regulating agent of the present invention have an effect of suppressing an increase in blood glucose level or an intestinal regulating effect, and can be used as an oral agent, and thus have high industrial usefulness.

Claims (4)

Processed barley and at least one processed plant material selected from the group consisting of terminaria, hops, mulberry, chlorella, kale, long-lived grass, sweet potato, curcuma longa, ginger, soybean, salasia, gymnema, guaba, and tochu. , A blood glucose elevation inhibitor characterized by containing. Processed barley and at least one processed plant material selected from the group consisting of terminaria, hops, mulberry, chlorella, kale, long-lived grass, sweet potato, curcuma longa, ginger, soybean, salasia, gymnema, guaba, and tochu. An intestinal regulator characterized by containing,. The agent for suppressing an increase in blood glucose level according to claim 1, which is a tablet, a granule, a powder or a capsule. The intestinal regulating agent according to claim 2, which is a tablet, a granule, a powder or a capsule.

Images